MMJ BioScience team is focused on transforming medical cannabis clinical development by connecting healthcare data, new technologies, advanced methodologies and scientific expertise.
Buffalo, New York (PRWEB)
July 30, 2017
MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and operation of medical cannabis healthcare businesses, today announced that its affiliate MMJ Bioscience has engaged QuintilesIMS has their Contract Research Organization. QuintilesIMS has been recognized as the Best Full-service Provider Contract Research Organization (CRO).
With a global team of 50,000 QuintilesIMS will assist MMJ BioScience in providing a new level of understanding around what clinical outcomes lead to commercial success in the development process of MMJ Bioscience’s first pharmaceutical formulation of cannabinoid (CBD) derived from certain extracts of the cannabis plant.
Working alongside the principal investigator Bianca Weinstock-Guttman,MD, a Professor of Neurology at the State University of New York at Buffalo who also serves as the Executive Director of the New York State Multiple Sclerosis Consortium, MMJ BioScience will access vast amounts of patient healthcare data from the progressive Multiple Sclerosis study. The MMJ BioScience team is focused on transforming medical cannabis clinical development by connecting healthcare data, new technologies, advanced methodologies and scientific expertise – these capabilities will distinguish the company as a leader in the medical cannabis business and significantly improve clinical trial results.
MMJ BioScience’s phase 2 studies will explore the potential therapeutic applications of cannabinoids across a broad range of multiple sclerosis disease areas for an orphan indication with a particular focus on neurological conditions. Dr. Weinstock-Guttman has been involved in multiple pivotal therapeutic clinical trials in MS and currently is involved in multiple phase III studies as well as in investigator-initiated phase I and IV studies. She has published more than 150 peer-reviewed articles in Neurology and Immunology medical journals. Her current special research interests…